Market News & Trends
Silo Pharma Expands Intellectual Property Portfolio With Provisional Patent
Silo Pharma, Inc. recently announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15.…
Artelo Biosciences Announces New Data on ART12.11 Tablets Showing Improved Pharmacokinetics to Epidiolex
Artelo Biosciences, Inc. recently announced nonclinical results on ART12.11, its proprietary cocrystal composition of cannabidiol (CBD) and tetramethylpyrazine (TMP). The findings were presented by Professor Saoirse…
IN8bio Presents Positive Phase 1 Data Highlighting Durability of Remissions in High-Risk AML
IN8bio, Inc. recently presented Phase 1 data on its allogeneic gamma-delta T cell therapy, INB-100, at the 2025 Transplantation & Cellular Therapy (TCT) Meetings in…
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Bicara Therapeutics Inc. recently announced the first patients have been enrolled in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in combination with pembrolizumab…
Abcuro Announces $200 Million Financing to Advance its First-In-Class Medicine in Development for Inclusion Body Myositis
Abcuro, Inc. recently announced the closing of a $200-million Series C financing led by New Enterprise Associates (NEA) with Foresite Capital joining the round and…
Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology
Mangoceuticals, Inc. recenntly announced it is advancing its research into respiratory illness prevention technologies by focusing on finding a practical, everyday solution to combat avian…
MediWound Initiates the VALUE Global Phase 3 Pivotal Trial of EscharEx for Treatment of Venous Leg Ulcers
MediWound Ltd. recently announced the initiation of VALUE, a global, pivotal Phase 3 trial evaluating EscharEx for the treatment of venous leg ulcers (VLUs). “We…
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety & Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia
Silo Pharma, Inc. recently announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods…
Ocean Biomedical Announces Breakthrough Findings in EGFR-Mutant Lung Cancer & Plans for FDA Alignment on Next-Stage Development
Ocean Biomedical recently announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy candidates to favorably interact with tyrosine kinase inhibitors (TKI),…
Safi Biotherapeutics & ARMI BioFabUSA Initiate Collaboration to Support Large-Scale Development of mRBCs
Safi Biotherapeutics recently announced a collaboration focused on the manufacturing of Safi’s mRBCs to support regulatory requirements and initial clinical studies. “We are very excited…
Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis
Biodexa Pharmaceuticals PLC recently announced the US FDA has granted Fast Track designation for eRapa, a proprietary encapsulated form of rapamycin being developed for the…
Recipharm Expands Aseptic Filling Capabilities for Process Development, Pilot Scale & Clinical Supply
Recipharm recently announced a new modular sterile filling system specifically tailored for process development, pilot scale and clinical supply, is now fully operational at its…
Alumis & ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company
Alumis Inc. and ACELYRIN, INC. recently announced a definitive merger agreement under which Alumis and ACELYRIN will merge in an all-stock transaction. Martin Babler, President,…
Conduit Pharmaceuticals Transitions to Phase 2 of Sarborg Collaboration to Support AI-Driven Drug Development
Conduit Pharmaceuticals Inc. recently announced the successful completion of all milestones in Phase 1 of its strategic collaboration with Sarborg Limited. This transition to Phase…
Maze Therapeutics Doses First Patient in Phase 2 Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
Maze Therapeutics, Inc. recently announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in patients…
Thermo Fisher Scientific Launches International CorEvitas Clinical Registry in Adolescent Alopecia Areata
Thermo Fisher Scientific Inc. recently announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry, addressing a critical unmet need for real-world, adolescent-specific…
Gradalis Secures FDA Regenerative Medicine Advanced Therapy Designation for Investigational Personalized Immunotherapy for Advanced Ovarian Cancer
Gradalis, Inc. recently announced the US FDA has granted Gradalis’ personalized investigational cellular immunotherapy, Vigil (Gemogenovatucel-T) Regenerative Medicine Advanced Therapy (RMAT) designation based on favorable clinical…
Indaptus Therapeutics Receives Approval From Health Canada to Expand Clinical Trial of Decoy20
Indaptus Therapeutics, Inc. recently announced it has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This…
Annovis Announces First Patients Entered Into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease
Annovis Bio Inc. recently announced the first two patients have been entered into the pivotal Phase 3 study evaluating buntanetap in early AD. "The launch…
Quantum Biopharma Announces the Success of unbuzzd Clinical Trial
Quantum BioPharma Ltd. recently announced it has completed a double-blind, randomized, placebo-controlled crossover design clinical trial (NCT06505239) of its dietary supplement product unbuzzd, investigating its…
